Cidara Therapeutics, Inc.CDTXNASDAQ
LOADING
|||

Analyst Sentiment

Analysts lean bullish — 73% recommend buying.

Consensus Rating
Buy
11 analysts·Moderate coverage
73%
Rating Distribution
Strong Buy
19%
Buy
764%
Hold
327%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Earnings & Revenue Estimates

Earnings Surprises

Recent Analyst Actions

Nov 14, 2025RBC Capital
Cidara downgraded to Sector Perform from Outperform at RBC Capital
Target:$221.50
+1.7%from $217.71
Oct 9, 2025H.C. Wainwright
Cidara Therapeutics price target raised to $150 from $110 at H.C. Wainwright
Target:$150.00
+38.7%from $108.18
Oct 3, 2025JMP Securities
Cidara Therapeutics price target raised to $173 from $153 at Citizens JMP
Target:$173.00
+75.6%from $98.50
Sep 26, 2025H.C. Wainwright
Cidara Therapeutics price target raised to $110 from $74 at H.C. Wainwright
Target:$110.00
+27.0%from $86.59
Sep 24, 2025JMP Securities
Cidara Therapeutics price target raised to $153 from $66 at Citizens JMP
Target:$153.00
+73.2%from $88.32
Sep 24, 2025Guggenheim
Cidara Therapeutics price target raised to $167 from $70 at Guggenheim
Target:$167.00
+92.7%from $86.67
Sep 24, 2025RBC Capital
Cidara Therapeutics price target raised to $137 from $115 at RBC Capital
Target:$137.00
+54.7%from $88.58
Jul 9, 2025Guggenheim
Cidara Therapeutics (CDTX) PT Raised to $69 at Guggenheim
Target:$69.00
+35.4%from $50.96
Jun 24, 2025Guggenheim
Cidara Therapeutics price target raised to $68 from $50 at Guggenheim
Target:$68.00
+45.2%from $46.84
May 16, 2025Guggenheim
Cidara Therapeutics price target raised to $50 from $35 at Guggenheim
Target:$50.00
+96.1%from $25.50
Mar 12, 2025JMP Securities
Cidara Therapeutics initiated with an Outperform at Citizens JMP
Target:$46.00
+119.0%from $21.00
Aug 14, 2024H.C. Wainwright
H.C. Wainwright Upgrades Cidara Therapeutics (CDTX) to Buy
Target:$24.00
+273.3%from $6.43